Loading
Alcestobart is an experimental monoclonal antibody from Nanjing Leads Biolabs, in phase 2 trials for nasopharyngeal carcinoma and melanoma.
Alcestobart (LBL-007) is a monoclonal antibody (fully human IgG4) from Nanjing Leads Biolabs. A fully human IgG4 antibody against LAG-3 that blocks LAG-3 binding to its inhibitory ligands and causes LAG-3 to be taken into the cell, reducing it on the cell surface. Its furthest stage is phase 2, for nasopharyngeal carcinoma and melanoma. ClinicalTrials.gov registers it in 9 studies linked below. Whether it works in people has not been established unless a trial below reports it.
A fully human IgG4 antibody against LAG-3 that blocks LAG-3 binding to its inhibitory ligands and causes LAG-3 to be taken into the cell, reducing it on the cell surface. Connects to LAG-3.
1.Alcestobart binds LAG-3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Alcestobart" OR ABSTRACT:"Alcestobart" OR TITLE:"LBL-007" OR ABSTRACT:"LBL-007") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Alcestobart, not a curated reading list.
Shares Nanjing Leads Biolabs, Melanoma and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares LAG-3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/